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  The	   journey	  of	   therapeutic	  development	   from	  concept	   to	   the	  market	   is	  a	   complex,	   lengthy	  and	  expensive	   process.	   Plant	   expression	   systems	   have	   been	   envisioned	   to	   provide	   solutions	   to	   the	  later	   phase	   of	   bulk	   production,	   by	   enabling	   cost	   effective	   manufacturing	   of	   high	   amounts	   of	  therapeutics.	   	   To	   realize	  higher	   expression,	   several	   innovative	   tools	  have	  been	  developed	  over	  the	  past	  20	  years	  for	  various	  plant	  organs,	  especially	  leaves	  and	  seeds.	  These	  developments	  have	  enabled	  bulk	  therapeutic	  production,	  but	  can	  also	  make	  an	  unparalleled	  contribution	  in	  the	  early	  phase	  of	  therapeutic	  discovery	  and	  drug	  optimisation.	  	  	  Our	   group	   has	   been	   exploring	   the	   prospects	   of	   transient	   expression	   in	  Nicotiana	  benthamiana	  and	   stable	   expression	   in	  Arabidopsis	   seeds	   for	   early	   stage	   exploration	   of	   candidate	   antibodies	  and	   antigens.	   The	   flexibility	   of	   plant	   expression	   system	   has	   permitted	   designing	   formats	  with	  various	  permutations	  and	  combinations	  of	  protein.	  At	  the	  PBVAB-­‐2015	  platform	  we’ll	  present	  an	  example	  of	  each	  of	  the	  two	  expression	  systems.	  	  	  	  As	  a	  solution	  to	  the	  recurrent	  diarrhea	  causing	  bacterial	  infection	  of	  F4-­‐bearing	  enterotoxigenic	  
Escherichia	   coli	   (ETEC)	   in	   piglets;	   anti-­‐ETEC	   IgG	   and	   IgA	   antibodies	   were	   produced	   in	  Arabidopsis.	   Kilograms	   of	   antibody	   producing	   Arabidopsis	   seeds	   enabled	   in	   vivo	   evaluation	   of	  oral	  feed	  based	  passive	  immunisation	  in	  a	  piglet	  challenge	  experiment.	  This	  led	  to	  the	  evidence,	  that	   the	   IgA	   isotypes	   of	   antibodies	   are	   more	   suitable	   than	   IgG	   in	   oral	   prophylaxis	   of	   weaned	  piglet	  against	  ETEC.	  	  	  In	  N.	  benthamiana,	  heterologous	  proteins	  can	  be	  produced	  in	  about	  five	  days	  and	  micrograms	  of	  different	   proteins	   can	   be	   produced	   in	   each	   leaf.	   Utilizing	   this	   benefit	   together	  with	   the	   recent	  modular	   cloning	   tools,	   we	   are	   investigating	   a	   wide	   combinatorial	   range	   of	   antigen-­‐antibody	  fusion	  molecules	  that	  can	  effectively	  cross	  the	  gut	  barrier	  and	  lead	  to	  mucosal	  immunity.	  	  The	  gut	  barrier	   is	   a	   selectively	  permeable	  membrane,	  were	   transcytosed	  antigens	   can	  either	   induce	  an	  immune	  reaction	  or	  a	  tolerogenic	  reaction.	  Among	  parameters,	  specific	  targeting	  to	  immune	  cells	  is	  important.	  Our	  approach	  aims	  at	  modulating	  the	  antigen-­‐antibody	  fusion	  molecule	  to	  fine-­‐tune	  enhanced	   uptake,	   thusly	   it’s	   anticipated	   to	   further	   the	   fundamental	   understanding	   of	  mucosal	  immunity	  and	  designing	  of	  oral	  therapeutics.	  	  
